Biochemical bone markers and biological effects of osteoporosis therapy

被引：2

作者：

Branka, Kovacev-Zavisic ^{[1
]}

Jovanka, Novakovic-Paro ^{[1
]}

Nikola, Curic ^{[2
]}

Tijana, Icin ^{[1
]}

Ljiljana, Todorovic-Djilas ^{[1
]}

Nemanja, Kovacev ^{[3
]}

机构：

[1] KC Vojvodine, Klin Endokrinologiju Dijabetes & Bolesti Metab, Novi Sad 21000, Serbia

[2] KC Vojvodine, Zavod Lab Med, Novi Sad 21000, Serbia

[3] Inst Plucne Bolesti Vojvodine, Sremska Kamenica, Serbia

来源：

VOJNOSANITETSKI PREGLED | 2012年 / 69卷 / 05期

关键词：

osteoporosis; biological markers; drug therapy; diagnosis; treatment outcome; VERTEBRAL FRACTURE; POSTMENOPAUSAL WOMEN; ELDERLY-WOMEN; TURNOVER; ALENDRONATE; MANAGEMENT; SERUM; RISK; TERIPARATIDE; IBANDRONATE;

D O I：

10.2298/VSP1205432K

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：432 / 436

页数：5

共 52 条

[1] Inhaled corticosteroids and fracture risk - Having our cake and eating it too
Aris, R
Donohue, JF
Ontjes, D
Hill, C
[J]. CHEST, 2005, 127 (01) : 5 - 7
[2] Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: The Fracture Intervention Trial
Bauer, DC
Black, DM
Garnero, P
Hochberg, M
Ott, S
Orloff, J
Thompson, DE
Ewing, SK
Delmas, PD
[J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 (08) : 1250 - 1258
[3] Monthly ibandronate suppresses serum CTX-I within 3 days and maintains a monthly fluctuating pattern of suppression
Binkley, N.
Silverman, S. L.
Simonelli, C.
Santiago, N.
Kohles, J. D.
Dasic, G.
Sunyecz, J. A.
[J]. OSTEOPOROSIS INTERNATIONAL, 2009, 20 (09) : 1595 - 1601
[4] The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis
Black, DM
Greenspan, SL
Ensrud, KE
Palermo, L
McGowan, JA
Lang, TF
Garnero, P
Bouxsein, ML
Bilezikian, JP
Rosen, CJ
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (13) : 1207 - 1215
[5] Quantifying the material and structural determinants of bone strength
Bouxsein, Mary L.
Seeman, Ego
[J]. BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2009, 23 (06): : 741 - 753
[6] BRANDI ML, 2009, RHEUMATOLOGY OXFO S4, V48, P3
[7] Bublous A, 2009, TUNIS MED, V87, P380
[8] Bunyaratavej Narong, 2009, J Med Assoc Thai, V92 Suppl5, pS116
[9] Does early PTH treatment compromise bone strength? The balance between remodeling, porosity, bone mineral, and bone size.
Burr D.B.
[J]. Current Osteoporosis Reports, 2005, 3 (1) : 19 - 24
[10] Use of biochemical markers of bone turnover in the management of postmenopausal osteoporosis
Camacho, Pauline M.
Lopez, Norma A.
[J]. CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2008, 46 (10) : 1345 - 1357

← 1 2 3 4 5 6 →